NuvOx Closed Oversubscribed Convertible Notes
Tucson, AZ, September 18th, 2023 NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round,...
top of page
NuvOx Announces Publication of Research Article in Cancer Research Communication
Tucson, AZ, August 28th, 2023 NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a...
NuvOx Announces BARDA Partnership for a Phase Ib ARDS/COVID Trial in Canada
Tucson, AZ, August 4th, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to...
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
Tucson, AZ, May 30, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
NuvOx Receives SPAN Grant
NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion Tucson, AZ, ...
NuvOx Newly Issued US Patent
The issued patent has claims for methods of use of DDFPe for stroke treatment.
NuvOx Pharma Announces Issuance of a New Patent
Award of this patent broadens NuvOx’s extensive patent portfolio of perfluorocarbon-based therapeutic formulations to reverse hypoxia.
NuvOx Appoints Dr. Robert King to SAB
Tucson, AZ, May 9th, 2022 – https://www.pr.com/press-release/861001 NuvOx Pharma, a clinical stage biotechnology company developing a...
NuvOx Technology Featured in Prominent Peer Review Journal
Tucson, AZ, April 19, 2022 -- https://www.pr.com/press-release/859633 NuvOx Pharma’s technology, which is developed as a first-in-class...
NuvOx Finalizes Facility Certification, Poising for Phase IIb Trials
Tucson, AZ, April 17, 2022 -- https://www.pr.com/press-release/859467 NuvOx Pharma, a clinical stage biotechnology company developing a...
NuvOx Receives Notice from the Breakthrough DOD Award for its Immuno-Oncology Program
On February 11th, 2022,-- https://www.pr.com/press-release/859467 NuvOx Pharma received notice from the Department of Defense (DOD)...
NuvOx to Participate in the BIO CEO Investor Conference
Tucson, AZ, February 10, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
NuvOx to Present at Various Bio Forums in JPM Week Tucson, AZ, January 7, 2022
Tucson, AZ, January 7, 2022 – NuvOx Pharma, a clinical stage biotechnology company developing a first-in-class therapeutic to treat...
NuvOx Pharma Receives Phase I STTR Grant from NINDS for Preclinical Studies in Stroke
Tucson, AZ, October 12, 2021 --(PR.com)-- NuvOx Pharma, a Tucson based biotechnology company, has received a $478,000 NIH Phase I Small...
NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy
Tucson, AZ, September 09, 2021 --(PR.com)-- NuvOx Pharma, a biotechnology company based in Tucson, Arizona, has generated positive...
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM
Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they...
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer
Tucson, AZ, July 23, 2021 --(PR.com)-- NuvOx Pharma, a privately-held clinical-stage biotechnology company based in Tucson, Arizona, has...
Tucson's NuvOx adds plant to make drugs in-house
A tandem of homegrown Tucson drug-development companies plans to make its own drugs for testing at a new manufacturing plant — and...
NuvOx Completes Construction of Expanded Manufacturing Facility
A new GMP production facility including an ISO 5 cleanroom has been constructed and has initiated operations. Click here to read more...
NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors
"We are honored and excited to have Jon Saxe join our board," said Evan Unger MD, President and CEO of NuvOx. "His broad knowledge of the...
Hunniwell Lake Ventures Spotlights NuvOx
Hunniwell Lake Ventures interviews NuvOx Co-founder and CEO, Evan Unger MD.
Health Canada Allows Phase IIa Clinical Trial in COVID-19 Patients with Respiratory Failure
Health Canada allows a Phase IIa Trial in COVID-19 patients with Respiratory Failure
NuvOx Expands Production Line
NuvOx Pharma is breaking ground on an addition to its manufacturing facility. Read full story
NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial
Positive results of NuvOx Pharma’s NanO2 (DDFPe) in the treatment of stroke have been published at the International Stroke Conference. A...
NuvOx Wins TechConnect Defense Innovation Award
NuvOx was awarded the TechConnect Defense Innovation Award based on the potential impact the technology will have on national security.
NuvOx Pharma wins AZBio Fast Lane Award
NuvOx was honored with the AZBIO Fast Lane Award for the company's many achievements in the last 18 months.
National Cancer Institute Grants $3M to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer
The NCI Grants $3M to NuvOx for a Phase II clinical trial in the brain cancer, glioblastoma.
NuvOx Wins MedCity INVEST Perfect Pitch Contest
NuvOx Pharma wins 1st place out of the biopharma companies at the MedCity INVEST Perfect Pitch Contest.
NuvOx wins Venture Madness competition and $60,000 prize.
NuvOx wins 1st place out of 113 entrants and a $60,000 cash prize.
bottom of page